Zenas BioPharma (ZBIO) Current Assets (2023 - 2026)

Zenas BioPharma's Current Assets history runs 4 years deep, the most recent figure standing at $730.2 million for Q1 2026.

• In Q1 2026, Current Assets rose 129.75% year-over-year to $730.2 million; the TTM figure through Mar 2026 stood at $730.2 million (up 129.75% YoY), while the FY2025 annual figure was $351.2 million, down 1.34% from the prior year.
• Current Assets was $730.2 million for Q1 2026 at Zenas BioPharma, up from $351.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $730.2 million in Q1 2026 to a low of $59.8 million in Q4 2023.
• Historically, Current Assets has averaged $348.0 million across 4 years, with a median of $334.5 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Current Assets jumped 495.15% in 2024, then slipped 24.67% in 2025.
• A 4-year view of Current Assets shows it stood at $59.8 million in 2023, then surged by 495.15% to $355.9 million in 2024, then decreased by 1.34% to $351.2 million in 2025, then jumped by 107.92% to $730.2 million in 2026.
• The last three Current Assets figures came in at $730.2 million (Q1 2026), $351.2 million (Q4 2025), and $296.6 million (Q3 2025), per Business Quant data.